Our news
Latest Achievements and Innovations by CanChip
Ghazaleh Madani Named “Newcomer of the Year 2025” at the German Start Up Awards
We are proud and grateful to share that our CEO, Ghazaleh Madani, has been awarded “Newcomer of the Year” at the German Start Up Awards 2025. Presented annually by the German Startups Association, this national honor recognizes founders who stand out through exceptional innovation, social relevance, and entrepreneurial courage.
Ghazaleh was recognized for her visionary leadership in founding and building CanChip GmbH, a pioneering biotech company that is transforming preclinical cancer research with its Tumor-on-Chip technology.
The innovation behind CanChip is based on integrating human tumor tissue into miniaturized microfluidic systems to simulate real-life biological conditions – enabling drug testing that is faster, more precise, more ethical, and patient-specific.
This breakthrough platform empowers pharmaceutical companies and research institutions to evaluate the efficacy and safety of drug candidates in human-relevant models – reducing the need for animal testing, accelerating development timelines, and offering greater hope for cancer patients worldwide.
What makes CanChip truly unique is also the personal story behind it. Ghazaleh’s motivation stems from her mother’s battle with cancer, which inspired her belief that there must be a better way to develop life-saving therapies – driven by science, guided by ethics, and enabled by technology.
The German Start Up Award is a tribute not only to a remarkable founder, but to a vision that unites science, innovation, and human empathy.
We warmly congratulate Ghazaleh on this exceptional honor – and thank all our supporters who believe in CanChip’s mission.
CanChip Nominated for the Brandenburg Innovation Award 2025
We are proud to announce that CanChip GmbH has been nominated for the Brandenburg Innovation Award 2025, an honor presented annually by the Ministry of Economic Affairs, Labour and Energy of the State of Brandenburg. The award recognizes outstanding projects that combine technological advancement with economic impact and social value.
With its Tumor-on-Chip technology, CanChip is developing a platform that could transform preclinical cancer research. The innovation makes it possible to cultivate real tumor cells within microfluidic chip systems, enabling drug testing under highly realistic conditions – without animal testing, faster, more precise, and patient-focused.
At the heart of the technology are miniaturized models of human tumor tissue that simulate complex cell behavior and drug interactions in real time. This breakthrough paves the way for more effective and personalized therapies – a crucial step toward individualized oncology.
“We are truly honored by this nomination – it’s a meaningful recognition of our team and our vision,” says Ghazaleh Madani, CEO of CanChip GmbH. “It shows that high-impact biotech innovation from Brandenburg can contribute meaningfully to global medical progress.”
The award ceremony will take place on July 10, 2025, in Cottbus. Even the nomination itself is a strong signal: CanChip stands for cutting-edge research, ethical responsibility, and international ambition – made in Brandenburg.
CanChip Wins First Place at PSP Conference Startup Pitch
At the PSP Conference 2024 held at Potsdam Science Park, CanChip GmbH proudly secured first place in the startup pitch competition. The event showcased top innovations in biotechnology, and CanChip’s groundbreaking “cancer-on-chip” technology impressed both the jury and attendees. This achievement highlights CanChip’s leadership in cancer research and innovation.
The PSP Conference 2024, held at Potsdam Science Park, celebrated innovation and collaboration in biotechnology, featuring groundbreaking research, industry partnerships, and a highly anticipated startup pitch competition. Among the highlights of this year’s event, CanChip GmbH proudly took first place in the startup pitch competition, impressing both the jury and attendees with its innovative cancer-on-chip solutions.
The annual PSP Conference serves as a platform for showcasing cutting-edge developments in life sciences and technology while fostering connections between researchers, startups, and industry stakeholders. This year’s startup pitch featured a diverse lineup of young companies presenting visionary ideas aimed at solving critical global challenges.
CanChip’s pioneering approach to personalized drug testing and microfluidic chip technology resonated strongly with the audience. By enabling more accurate and efficient cancer research, the company’s solutions are poised to revolutionize the field. The victory reinforces CanChip’s position as a leader in the biotech sector and highlights the dynamic innovation ecosystem fostered at Potsdam Science Park.
CanChip Wins First Place at EUTECH SDG Awards in SDG3 Category
CanChip GmbH has won first place in the SDG 3 category of the prestigious EUTECH SDG Awards 2024, which recognize initiatives that contribute significantly to achieving the United Nations’ Sustainable Development Goals (SDGs). This remarkable achievement highlights CanChip’s innovative approach to advancing global health and well-being through its cutting-edge cancer-on-chip research, providing breakthrough solutions for more effective drug testing and cancer treatment.
The SDG Awards, hosted by the SDG Alliance of the European Technology Chamber, celebrate projects that demonstrate a profound commitment to sustainable development and social impact. Winning this award reinforces CanChip’s dedication to improving health outcomes and fostering technological advancements that benefit society globally.
CanChip Wins the Prestigious Guido Reger Gründungspreis
We are thrilled to announce that CanChip GmbH has been awarded the Guido Reger Gründungspreis, a recognition of innovation and excellence in the startup community. This prestigious award acknowledges our commitment to advancing cancer research through cutting-edge microfluidic chip technology.
As the CEO of CanChip GmbH, I am incredibly proud of our team’s dedication and passion in developing our unique solutions for cancer research. This award is not only a testament to our progress but also a powerful motivator as we continue to push the boundaries of cancer-on-chip technology.
Thank you to the Guido Reger Foundation for this honor, and to all those who have supported us on our journey. We are excited for the next chapter and look forward to further contributing to the scientific community.
External Quality Report: 3D-Printed Microfluidic Devices for Drug Absorption Studies
We are thrilled to share the outcomes of our recent collaboration with the Fraunhofer Institute for Applied Polymer Research (IAP) on assessing drug absorption in our 3D-printed microfluidic devices.
The report focused on the performance of these devices using 5-Fluorouracil (5FU) as a model drug. Over 72 hours of testing, absorption characteristics were measured using advanced UV-Vis spectrophotometry. This data validates the precision and reliability of our chips for controlled drug absorption studies, highlighting their potential for pharmaceutical research applications.
This partnership underscores our commitment to quality and innovation in microfluidic technology. Stay tuned as we continue to push boundaries in this exciting field!
New White Paper: Transforming Colorectal Cancer Research with "CRC-on-a-Chip"
We are excited to announce the release of our latest white paper, Advancing Colorectal Cancer Research, showcasing the innovative “CRC-on-a-Chip” technology. This 3D-printed microfluidic platform enables co-culturing of colorectal cancer cells (HCT116) and endothelial cells (HUVECs) to replicate the tumor microenvironment and study angiogenesis in a physiologically relevant setting.
The white paper highlights breakthroughs in gene expression analysis, 3D tumor modeling, offering a scalable, ethical, and cost-effective alternative to traditional methods. By mimicking complex biological interactions, this platform paves the way for new treatments and therapies in colorectal cancer research.
Learn more about this transformative technology and download the white paper on our website.
